607 related articles for article (PubMed ID: 34304604)
1. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
3. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
4. Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke.
Hilkens NA; Algra A; Kappelle LJ; Bath PM; Csiba L; Rothwell PM; Greving JP;
Neurology; 2018 Feb; 90(8):e683-e689. PubMed ID: 29374102
[TBL] [Abstract][Full Text] [Related]
5. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
7. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Chaturvedi S
Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists.
Fintel DJ
Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044
[TBL] [Abstract][Full Text] [Related]
9. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Simmons BB; Yeo A; Fung K; ;
Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
[TBL] [Abstract][Full Text] [Related]
10. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Guthrie R
Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
[TBL] [Abstract][Full Text] [Related]
11. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
12. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Lee M; Saver JL; Hong KS; Rao NM; Wu YL; Ovbiagele B
Ann Intern Med; 2013 Oct; 159(7):463-70. PubMed ID: 24081287
[TBL] [Abstract][Full Text] [Related]
13. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Zhang Q; Wang C; Zheng M; Li Y; Li J; Zhang L; Shang X; Yan C
Cerebrovasc Dis; 2015; 39(1):13-22. PubMed ID: 25547900
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Ding L; Peng B
Eur J Neurol; 2018 Oct; 25(10):1276-1284. PubMed ID: 29855121
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
[TBL] [Abstract][Full Text] [Related]
18. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Diener HC
Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
[TBL] [Abstract][Full Text] [Related]
19. Aspirin plus clopidogrel
Ye MB; Chen YL; Wang Q; An J; Ye F; Jing P
Scand Cardiovasc J; 2019 Aug; 53(4):169-175. PubMed ID: 31112048
[No Abstract] [Full Text] [Related]
20. Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Skliut M; Jamieson DG
Curr Cardiol Rep; 2008 Feb; 10(1):9-16. PubMed ID: 18416995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
